Did you know?

ChinaBio® Group is a consulting and advisory firm helping life science companies and investors achieve success in China. ChinaBio works with U.S., European and APAC companies and investors seeking partnerships, acquisitions, novel technologies and funding in China.  

Learn more >>

Free Newsletter

Have the latest stories on China's life science industry delivered to your inbox daily or weekly - free!

See preview >>

  Email address:
   

AnHeart Sells Japanese Rights to ROS1 TKI to Nippon Kayaku for $40 Million Upfront

publication date: Oct 31, 2023

AnHeart Therapeutics, a New York-Shanghai biopharma, sold Japanese rights for its lead drug, a ROS1 tyrosine kinase inhibitor to Nippon Kayaku for $40 million upfront plus unspecified milestone and royalty payments. Last week, AnHeart reported that taletrectinib, its next-gen ROS1 inhibitor, shrank tumors in 92% of treatment-naïve patients with advanced ROS1-positive non-small cell lung cancer (NSCLC) in a global Phase II trial. Nippon Kayaku will have rights to that indication along with others of its own choosing. AnHeart will continue taletrectinib trials for NSCLC and will supply the drug Nippon Kayaku for Japan commercialization. More details....

Share this with colleagues:  


This article is available for purchase - please click here for details.

Sorry this page is available to subscribers only.
If you're not a subscriber why not subscribe today?

If you are already a subscriber, please login.

If you believe you should have received this message in error, please contact us.


 

To gain access to the members only content click here to subscribe.

You will be given immediate access to premium content on the site.

ChinaBio® News

Greg Scott BIO-Europe Interview
Greg Scott Interviewed at BIO-Europe Spring

How to bring your China assets to China in 8 minutes

Greg Scott Mendelspod Interview
"Mr. Bio in China."
Mendelspod Interview

Multinational pharma held to a higher standard in China

Partner Event
November 2-3, 2023 | Shanghai
November 7-8, 2023 | Digital